| ¿µ¹® | hemolytic anemia | ÇÑ±Û | ¿ëÇ÷ºóÇ÷ |
|---|---|---|---|
| ¼³¸í | ¿ëÇ÷ºóÇ÷À̶õ ÀûÇ÷±¸ÀÇ °úµµÇÑ ÆÄ±«¿¡ ÀÇÇÑ ºóÇ÷ÀÌ´Ù. ¿ø·¡ 120ÀÏ Á¤µµÀÇ ¼ö¸íÀ» °¡Áö´Â ÀûÇ÷±¸ÀÇ ¼ö¸íÀÌ Âª¾ÆÁö´Â °ÍÀÌ´Ù. ¿©±â¿¡´Â ¿©·¯ °¡Áö ¿øÀÎÀÌ ÀÖÀ» ¼ö°¡ Àִµ¥ ´ëÇ¥ÀûÀÎ ¿øÀÎÀ¸·Î´Â ÀûÇ÷±¸¿¡ ´ëÇÑ Ç×ü°¡ »ý±â´Â °Í(¹ßÀÛ¼º¾ß°£Ç÷»ö¼Ò´¢Áõ)°ú ÀûÇ÷±¸ÀÚüÀÇ ÀÌ»ó(À¯Àü¼ºµÕ±ÙÀûÇ÷±¸Áõ), ±×¸®°í ´Ù¸¥ Áúº´¿¡ ÀÇÇØ¼ 2Â÷ÀûÀ¸·Î »ý±â´Â °ÍÀÌ ÀÖ´Ù. |
||
| ¿µ¹® | autoimmune dieases | ÇÑ±Û | ÀÚ°¡¸é¿ªÁúȯ |
|---|---|---|---|
| ¼³¸í | ¸é¿ªÀ̶õ ¿Ü°è¿¡¼ µé¾î¿Â ¹°ÁúÀ» ÆÄ±«Çϰųª ¹«±â·ÂÈ ½ÃÄѼ ÀÚ½ÅÀ» º¸È£ÇÏ´Â ÀÏ·ÃÀÇ ÀÛ¿ëÀ» ¸»ÇÑ´Ù. ¸é¿ª¿¡¼ °¡Àå Áß¿äÇÑ ´Ü°è´Â ÀڽŰú ¿ÜºÎ¿¡¼ µé¾î¿Â ¹°ÁúÀ» ±¸ºÐÇÏ´Â °ÍÀÌ´Ù. ÀÚ°¡ ¸é¿ªÁúȯÀ̶õ ÀÌ·± ÀڽŰú ¿ÜºÎ¿¡¼ µé¾î¿Â ¹°ÁúÀÇ ±¸ºÐÀÌ È®½ÇÇÏÁö ¸øÇÏ¿© ÀÚ½ÅÀÇ ¹°Áú·Î À߸ø ÀνÄÇÏ¿© ½º½º·Î ÀÚ½ÅÀÇ ¹°ÁúÀ» ÆÄ±«ÇÏ´Â º´À» ¸»ÇÑ´Ù. |
||
| ¿µ¹® | hemolytic disease of newborn | ÇÑ±Û | ½Å»ý¾Æ¿ëÇ÷º´ |
|---|---|---|---|
| ¼³¸í | ½Å»ý¾Æ¿¡¼ ÀûÇ÷±¸°¡ ºñÁ¤»óÀûÀ¸·Î ¸¹ÀÌ ÆÄ±«µÇ´Â º´À¸·Î žÆÀû¸ð±¸Áõ(erythroblastosis fetalis)¿Í °°Àº ¶æÀ¸·Î ¾²ÀδÙ. À̰ÍÀº ¾î¸Ó´Ï¿¡°Ô¼ »ý»êµÈ ½Å»ý¾Æ³ª žÆÀÇ ÀûÇ÷±¸¿¡ ´ëÇÑ Ç×ü°¡ ŹÝÀ» °Ç³Ê¿Í¼ žÆÀÇ ÀûÇ÷±¸¿Í °áÇÕÇÏ¿©¼ »ý±â´Â ¿ëÇ÷¼ººóÇ÷À» À̸£´Â ¸». Áï ½Å»ý¾Æ³ª žÆÀÇ ÀûÇ÷±¸ÀÇ Ç×ü°¡ ¾î¸Ó´ÏÀÇ ¸ö¿¡¼ »ý»êÀÌ µÇ°í À̰ÍÀÌ Å¹ÝÀ» ÅëÇØ¼ žƿ¡°Ô ³Ñ¾î°¡¼ žÆÀÇ ÀûÇ÷±¸¿Í °áÇÕÀ» Çϰí ÀÌ Ç×ü¿Í °áÇÕÇÑ ÀûÇ÷±¸´Â ÆÄ±«°¡ µÇ¾î¼ ºóÇ÷ÀÌ »ý±ä °ÍÀ» žÆÀû¸ð±¸ÁõÀ̶ó°í ÇÑ´Ù. À̰ÍÀº Rh Àû¸ð±¸Áõ(Rh erythroblastosis)¿Í ABO Àû¸ð±¸Áõ(ABO erythroblastosis)·Î ³ª´ ¼ö°¡ ÀÖ´Ù. |
||
| ¿µ¹® | anemia | ÇÑ±Û | ºóÇ÷ |
|---|---|---|---|
| ¼³¸í | Ç÷¾×ÀÌ ¼øÈ¯ÇÏ´Â ¸ñÀû Áß¿¡¼ °¡Àå Áß¿äÇÑ °ÍÀº ¿©·¯ °¡Áö ¿µ¾ç¼Ò¸¦ ¸»ÃÊÀÇ Àå±â·Î º¸±ÞÇÏ°í ¸»ÃÊÀÇ Àå±â¿¡¼ ³ª¿À´Â ¿©·¯ ³ëÆó¹°À» ÄáÆÏÀ̳ª Æó·Î º¸³» ¹è¼³¹°À» ó¸®ÇÏ´Â µ¥ ÀÖ´Ù. ±× Áß¿¡¼ »ê¼ÒÀÇ ¿î¹ÝÀº °¡Àå Áß¿äÇѵ¥ ¹Ù·Î ÀÌ »ê¼ÒÀÇ ¿î¹ÝÀ» ´ã´çÇÏ´Â °ÍÀÌ ÀûÇ÷±¸ÀÌ´Ù. ÀûÇ÷±¸¿¡´Â Ç÷»ö¼Ò¶ó´Â ¹°ÁúÀÌ ÀÖ¾î À̰ÍÀÌ »ê¼Ò¿Í °áÇÕÇÏ¿© »ê¼Ò¸¦ ¸»ÃÊÀÇ Àå±â·Î ¿î¹ÝÇÒ ¼ö°¡ ÀÖ´Ù. ºóÇ÷À̶õ ´ÜÀ§ºÎÇÇÀÇ Ç÷¾×¼Ó¿¡ ÀûÇ÷±¸ÀÇ ¾çÀÌ ÀûÀº °æ¿ì¸¦ ¸»ÇÑ´Ù. ÀûÇ÷±¸ÀÇ ¾çÀ» ³ªÅ¸³»´Â °ÍÀ¸·Î´Â 3°¡Áö ¹æ¹ýÀÌ ÀÖ´Ù. ÀûÇ÷±¸ÀÇ ¼ýÀÚ¸¦ Á÷Á¢ Ç¥ÇöÇÏ´Â ¹æ¹ý°ú, Ç÷»ö¼ÒÀÇ ¾çÀ» Á¤·®ÇÏ¿© ±× ¾çÀ» Ç¥½ÃÇÏ´Â ¹æ¹ý°ú, Ç÷¾×¼Ó¿¡¼ ÀûÇ÷±¸°¡ Â÷ÁöÇÏ´Â ¾ç(ÀûÇ÷±¸µîÀûÀ²)À» ³ªÅ¸³»´Â ¹æ¹ýÀÌ ±×°ÍÀÌ´Ù. ´ë°³ ºóÇ÷À̶ó ÇÔÀº ³²¼º¿¡¼ Ç÷»ö¼Ò < 14g/dl, Ç÷»ö¼Ò < 42%, ÀûÇ÷±¸ÀÇ ¼ö < 4,000,000/mm3ÀÏ °æ¿ìÀ̰í, ¿©¼º¿¡¼± Ç÷»ö¼Ò < 12g/dl, Ç÷»ö¼Ò < 36%, ÀûÇ÷±¸ÀÇ ¼ö < 3,300,000/mm3ÀÏ °æ¿ì¸¦ ÁöĪÇÑ´Ù. |
||
| ¿µ¹® | pernicious anemia | ÇÑ±Û | ¾Ç¼ººóÇ÷ |
|---|---|---|---|
| ¼³¸í | ¾Ç¼º(»ý¸íÀ» À§ÇùÇϸç, Ä¡·á¿¡ ÀúÇ×ÇÏ´Â °æ¿ì¿¡ ´ë°³ ¾Ç¼ºÀ̶ó ºÎ¸§. ¿¹¸¦ µé¾î ÁøÇàµÈ ¾ÏÀÇ °æ¿ì)À̶ó À̸§ºÙ¾î ÀÖÁö¸¸, ½ÇÁ¦ÀûÀ¸·Î´Â ¾Ç¼ºÀÌ ¾Æ´Ï´Ù. ºóÇ÷ÀÇ ÀÏÁ¾ÀÌ´Ù. Á¤»óÀûÀ¸·Î ÀûÇ÷±¸´Â ¹ß´Þ°ú ¼º¼÷°úÁ¤¿¡¼ ºñŸ¹Î B12°¡ ÇʼöÀûÀÌ´Ù. ÀÌ ºñŸ¹Î B12ÀÇ Ç÷Áß³óµµ°¨¼Ò¿¡ ÀÇÇØ ÀûÇ÷±¸»ý¼º¿¡ ÁöÀåÀ» °¡Á®¿À°Ô µÇ°í, Ç÷¾×³»¿¡ Ư¡ÀûÀÎ °Å´ëÀû¸ð±¸(megaloblast)ÀÇ Çü¼ºÀÌ ³ªÅ¸³ª´Â Áúº´À» ¸»ÇÑ´Ù. |
||
| AHA | acetohydroxamic acid; acquired hemolytic anemia; acute hemolytic anemia; American Heart Association;... |
|---|---|
| MHD | maintenance hemodialysis; mean hemolytic dose; mental health department; minimum hemolytic dilution;... |
| AHA | Autoimmune Hemolytic Anemia |
| AIHA | American Industrial Hygiene Association; autoimmune hemolytic anemia |
| IAHA | idiopathic autoimmune hemolytic anemia; immune adherence hemagglutination |
| MAHA | Microangiopathic hemolytic anemia |
|---|---|
| BHS | Beta-hemolytic streptococci |
| CH 50 | Complement hemolytic activity |
| DHTR | Delayed hemolytic transfusion reaction |
| GABHS | Group A beta hemolytic streptococcal |
| anemia | <haematology> Too few red blood cells in the bloodstream, resulting in insufficient oxygen to tissues and organs. Origin: Gr. Haima = blood (16 Dec 1997) |
|---|---|
| hemolytic anaemia | <disease, haematology> Anaemia resulting from reduced red cell survival time and haemolysis, either due to an intrinsic defect in the erythrocyte (hereditary spherocytosis or ellipsocytosis, enzyme defects, haemoglobinopathy) or an extrinsic damaging agent. For example autoantibody (autoimmune haemolytic anaemia), iso antibody, parasitic invasion of the cells (malaria), bacterial or chemical haemolysins, mechanical damage to erythrocytes. Origin: Gr. Haima = blood (18 Nov 1997) |
| anaemia, haemolytic, autoimmune | Acquired haemolytic anaemia due to the presence of autoantibodies which agglutinate or lyse the patient's own red cells. (12 Dec 1998) |
| autoimmune | <immunology> Pertaining to autoimmunity. (02 Jan 1998) |
| autoimmune disease | <disease> A disease process that involves the production of host antibodies to host tissue. (27 Sep 1997) |
| autoimmune diseases | Are illnesses which occur when the body tissues are attacked by its own immune system. The immune system is a complex organisation within the body that is designed normally to seek and destroy invaders of the body, particularly infections. Patients with these diseases have unusual antibodies in their blood that target their own body tissues. (12 Dec 1998) |
| autoimmune haemolytic anaemia | <haematology> A condition that results from the cellular destruction (haemolysis) of red blood cells due to antibodies formed to components on the surface of the red blood cells. Origin: Gr. Haima = blood (02 Jan 1998) |
| autoimmune hepatitis | <pathology> A type of chronic active hepatitis that results from circulating auto-antibodies and chronic inflammation of the liver. Symptoms are those of chronic active hepatitis. (27 Sep 1997) |
| autoimmune thrombocytopenia purpura | <haematology> A rare autoimmune disorder characterised by an acute shortage of platelets with resultant bruising and spontaneous bleeding. The platelet count becomes exceedingly low and spontaneous bleeding from the gums, gastrointestinal tract and nose can be seen. Physical examination may demonstrate enlargement of the spleen. A typical rash occurs to do microscopic haemorrhage of small blood vessels in the skin. Platelet counts under 10,000 can lead to spontaneous haemorrhage into the brain causing death. Treatment with corticosteroids is generally effective. Surgical removal of the spleen (splenectomy) is reserved for some patients. Anti-platelet antibodies are detectable in some cases. It may present in either an acute or a chronic form. Acronym: ITP (20 Sep 2002) |
| autoimmune thyroiditis | <endocrinology> Inflammation of the thyroid gland without the formation of pus. Noninfectious nonbacterial thyroid inflammation. (27 Sep 1997) |
| polyendocrinopathies, autoimmune | Autoimmune disease affecting multiple endocrine organs. Type I is characterised by childhood onset and mucocutaneous candidiasis, while type II exhibits any combination of adrenal insufficiency (addison's disease), lymphocytic thyroiditis, hypoparathyroidism, and gonadal failure. In both types organ-specific antibodies against a variety of endocrine glands have been detected. The type II syndrome differs from type I in that it is associated with HLA-a1 and b8 haplotypes, onset is usually in adulthood, and candidiasis is not present. (12 Dec 1998) |
| hepatitis, autoimmune | An unresolving, predominately periportal, hepatitis, usually with hypergammaglobulinaemia and serum autoantibodies. The existence of subgroups (types 1, 2, and 3) based on serological findings are controversial. Additionally, some patients have variant forms, where there are features associated with both autoimmune hepatitis and another type of chronic liver disease (overlap syndromes) or where there are findings incompatible with autoimmune hepatitis (outlier syndromes). (12 Dec 1998) |
| systemic autoimmune diseases | A group of connective tissue disease's characterised by the presence of autoantibodies responsible for immunopathologically mediated tissue lesions; systemic lupus erythematosus is the prototype. (05 Mar 2000) |
| thyroiditis, autoimmune | A progressive disease of the thyroid gland with antibodies in the blood stream directed against the thyroid and infiltration of the gland by lymphoctes (a key type of white blood cells involved in the immune response). This immune response is against one's own thyroid. (it is autoimmune.) predominantly affects women. Can be familial. Also called hashimoto's disease or hashimoto's thyroiditis. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|